ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
Adagio Therapeutics Inc

Adagio Therapeutics Inc (ADGI)

4.64
0.00
(0.00%)
마감 30 1월 6:00AM
0.00
0.00
(0.00%)
시간외 거래: -

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

주요 통계 및 세부정보

가격
4.64
매수가
4.52
매도가
4.74
거래량
-
0.00 일간 변동폭 0.00
0.00 52주 범위 0.00
market_cap
전일 종가
4.64
개장가
-
최근 거래 시간
마지막 거래 시간
재정 규모
-
VWAP
-
평균 볼륨(3m)
-
발행 주식
110,115,000
배당수익률
-
주가수익률
-2.57
주당순이익(EPS)
-1.8
매출
-
순이익
-198.64M

Adagio Therapeutics Inc 정보

Adagio Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company's lead product candidate, ADG20 is developed for the treatment and preven... Adagio Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company's lead product candidate, ADG20 is developed for the treatment and prevention of coronavirus disease 2019, or COVID-19, the disease caused by the virus SARS-CoV-2 and its variants. 더 보기

섹터
Biological Pds,ex Diagnstics
산업
Biological Pds,ex Diagnstics
웹사이트
본부
Wilmington, Delaware, USA
설립됨
-

ADGI 최신 뉴스

Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop

WALTHAM, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory...

Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer

WALTHAM, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory...

Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron Variants

Integrated discovery platform is producing a stream of candidate antibodies demonstrating broad in vitro neutralization against past variants of concern (e.g., D614G, beta, delta) and Omicron...

Adagio Therapeutics Announces Corporate Name Change to Invivyd

New name reflects Company focus on leveraging its integrated discovery platform to generate anti-viral antibodies that transcend the limits of naturally occurring immunityThe Invivyd corporate...

Adagio Therapeutics to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and...

Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

$475 Million in Cash and Cash Equivalents to Support Operating Runway into Second Quarter of 2024 Integrated Discovery Platform Identifies Multiple New Candidates for COVID-19 Prevention and...

Mithril Capital’s Ajay Royan Sends Letter Thanking Adagio Therapeutics Shareholders for Support of Successful Proxy Campaign

Adagio Shareholders Overwhelmingly Elected Mithril’s Three High-Quality Director Candidates To the Adagio Board Board Transformation will Advance Company’s Mission to Prevent and Treat COVID19...

Adagio Announces David Hering Named Permanent Chief Executive Officer and Director

WALTHAM, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...

Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board of Directors

WALTHAM, Mass., July 01, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...

Adagio Therapeutics Reports First Quarter 2022 Financial Results

$532.2 Million in Total Cash at Quarter End; Strong Balance Sheet Expected to Support Operations into Second Half of 2024 Additional Data from Adintrevimab Phase 2/3 STAMP Treatment Trial to be...

기간변동변동 %시가고가저가평균 일일 거래량VWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

ADGI - Frequently Asked Questions (FAQ)

What is the current Adagio Therapeutics share price?
The current share price of Adagio Therapeutics is US$ 4.64
How many Adagio Therapeutics shares are in issue?
Adagio Therapeutics has 110,115,000 shares in issue
What is the market cap of Adagio Therapeutics?
The market capitalisation of Adagio Therapeutics is USD 510.93M
What is the 1 year trading range for Adagio Therapeutics share price?
Adagio Therapeutics has traded in the range of US$ 0.00 to US$ 0.00 during the past year
What is the PE ratio of Adagio Therapeutics?
The price to earnings ratio of Adagio Therapeutics is -2.57
What is the reporting currency for Adagio Therapeutics?
Adagio Therapeutics reports financial results in USD
What is the latest annual profit for Adagio Therapeutics?
The latest annual profit of Adagio Therapeutics is USD -198.64M
What is the registered address of Adagio Therapeutics?
The registered address for Adagio Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE ST, NEW CASTLE, WILMINGTON, DELAWARE, 19801
What is the Adagio Therapeutics website address?
The website address for Adagio Therapeutics is invivyd.com
Which industry sector does Adagio Therapeutics operate in?
Adagio Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
DGNXDiginex Ltd
US$ 49.18
(228.09%)
3.34M
SLXNSilexion Therapeutics Corporation
US$ 3.1301
(131.86%)
330.45M
KRKR36Kr Holdings Inc
US$ 9.10
(114.12%)
23.61M
SPGCSacks Parente Golf Inc
US$ 0.6001
(57.92%)
52.17M
XFORX4 Pharmaceuticals Inc
US$ 0.7542
(56.54%)
42.49M
ZKINZK International Group Co Ltd
US$ 0.4813
(-41.21%)
3.1M
MGOLMGO Global Inc
US$ 0.1019
(-38.73%)
70.51M
BACKIMAC Holdings Inc
US$ 0.7869
(-35.50%)
2.37M
EYENEyenovia Inc
US$ 0.03695
(-35.18%)
25.31M
HAOHaoxi Health Technology Ltd
US$ 2.52
(-31.89%)
484.94k
NVDANVIDIA Corporation
US$ 123.70
(-4.10%)
466.93M
SLXNSilexion Therapeutics Corporation
US$ 3.1301
(131.86%)
330.45M
OCEAOcean Biomedical Inc
US$ 0.249929
(-24.26%)
186.51M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.428
(-6.98%)
148.12M
RIMEAlgorhythm Holdings Inc
US$ 0.0259
(-16.18%)
138.96M

ADGI Discussion

게시물 보기
INFINITI INFINITI 3 년 전
Let’s gooooo$$$
👍️0
INFINITI INFINITI 3 년 전
Let her run geez
👍️0
INFINITI INFINITI 3 년 전
Going to burst mark it $$$
👍️0
Penny chatter Penny chatter 3 년 전
On watch
👍️0
Penny chatter Penny chatter 3 년 전
Possible
👍️0
INFINITI INFINITI 3 년 전
I’m in looks good let’s gooo
👍️0
November61 November61 3 년 전
Short SQUEEZE and HALT on the menu today.

Might try to fill the gap to around 35 Dollars.
👍️0
jchords jchords 3 년 전
Can it test previous price zones?
👍️0
TheFinalCD TheFinalCD 3 년 전
https://finviz.com/quote.ashx?t=ADGI

https://finance.yahoo.com/news/adagio-therapeutics-announces-adg20-adintrevimab-103000765.html
👍️0
Awl416 Awl416 3 년 전
Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use Authorizat
👍️0
Tim696969 Tim696969 3 년 전
Is not a data read out coming this month?
👍️0
November61 November61 3 년 전
Not really! Antibodies direction is a solution that has been NOT pushed enough against covid.

We got the mask instead! So stupid.
👍️0
double_m double_m 3 년 전
Novavax announced approval in Canada just last week and preorder of 51M doses (possibly 61M) by Australia, and the market treated it like a dry fart! ADG20 is sooo late to the party I'm afraid!


Adagio Therapeutics Announces ADG20 Development Plans and Pipeline Updates
February 22 2022 - 07:30AM
GlobeNewswire Inc.

Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today outlined strategic initiatives for its ADG20 program, as well as research efforts to address SARS-CoV-2 and other coronaviruses. ADG20 is an investigational monoclonal antibody (mAb) being developed for the prevention and treatment of COVID-19.
👍️0
double_m double_m 3 년 전
This stock is so freaking disappointing! A whole week of small gains to lose it all in 1 day!!!
👍️0
Man6677 Man6677 3 년 전
Looking nice here

ADGI $$$$
👍️0
November61 November61 3 년 전
SQUEEZE and FILL the Gaps!

25 bucks will be just fine!
👍️0
November61 November61 3 년 전
Bought more at 5.80. Confident on that one.

And then a good squeeze is still on the table.

GLTA
👍️0
Man6677 Man6677 3 년 전
Very good !

Thanks .
👍️0
Disquisition Disquisition 3 년 전
January 16th: Listed on NASDAQ.com as one of the Top 5 biotech stocks to watch in January 2022:

https://www.nasdaq.com/articles/5-top-biotech-stocks-to-watch-in-january-2022?amp
👍️0
Man6677 Man6677 3 년 전
Very disappointing today after the news .
👍️0
November61 November61 3 년 전
Might see some SQUEEZE today!

20 bucks will be just fine.

Time to cover people.

My source says Omicron, while giving mild symptoms, has a contagious rate much higher than the previous variant. Around 70 times easier to catch. Once again, according to my Doctor.

Neutralizing Omicron is one way to fight it.

GO ADGI
👍️0
crudeoil24 crudeoil24 3 년 전
PT > 6.00 > recent multiple downgrades!
👍️0
Man6677 Man6677 3 년 전
Adagio soars 25% as studies suggest ADG20 neutralization activity against Omicron
Jan. 12, 2022 5:22 PMAdagio Therapeutics, Inc. (ADGI)By: Ravikash, SA News Editor
a corona virus omicron variant composition
Teka77/iStock via Getty Images

Adagio Therapeutics (NASDAQ:ADGI) said three separate publications that show that its lead monoclonal antibody (mAb) ADG20 has neutralization activity against the Omicron (B.1.1.529) variant of SARS-CoV-2, and outlined initiatives to address current and future SARS-CoV-2 variants of concern.

The company is evaluating ADG20 in its global Phase 2/3 trials for both the prevention and treatment of COVID-19.

Adagio said it is engaging with the U.S. Food and Drug Administration (FDA) regarding potential protocol updates to its global phase 2/3 trials, including an increased dose of ADG20 for the potential prevention and treatment of COVID-19 resulting from the Omicron variant.

The company said findings across all three studies show that among mAbs in late-stage clinical development or with Emergency Use Authorization (EUA), ADG20 is one of only a few mAbs that demonstrated neutralizing activity against Omicron. Across two distinct authentic neutralization assays against Omicron, the data show that ADG20 had an IC50, a measurement of neutralization potency, of approximately 0.4 to 1.1 µg/mL, which is comparable with the two other active mAbs, sotrovimab and AZD7742.

"While findings may show that ADG20 has reduced potency against Omicron when compared to its high potency against all other variants of concern, including Delta, the data support that ADG20 is among the few mAbs to demonstrate neutralizing activity against the Omicron variant and warrants its continued development,” said Laura Walker, Ph.D., chief scientific officer and co-founder of Adagio.

The company added that it is continuing evaluation of ADG20 in its EVADE and STAMP trials and engaging with the FDA on dosing strategy, including an increased dose of ADG20 and other protocol updates.

Adagio noted that it is pausing the enrollment of new patients in the 300 mg dose arm in both trials as the company updates its protocols. Follow-up and monitoring of patients previously administered ADG20 are continuing per the original protocols.

ADGI +25.73% after hours to $7.33

https://finviz.com/quote.ashx?t=ADGI&ty=c&ta=1&p=d

ADGI $$$$
👍️0
alchemytrader alchemytrader 3 년 전
oh boy...nice buy. 7.17 now off news after hours.
👍️0
November61 November61 3 년 전
Bought some! Now do the same and SQUEEZE!

20 bucks seems to be feasible
👍️0
Man6677 Man6677 3 년 전
Time to hear something here imo !

ADGI $$$
👍️0
Outcast27 Outcast27 3 년 전
I'am getting a azz wipping , MMs / Shorts ...I will hold a bit longer..Refuse to give them my money....Fukers
👍️0
Man6677 Man6677 3 년 전
Time for a update here !

ADGI $$$
👍️0
Man6677 Man6677 3 년 전
We hope the best

ADGI $$$
👍️0
Outcast27 Outcast27 3 년 전
Well this has gotten painful, but still holding , this Virus still is kicking but....And ADGI is still working on it , so I will give them a chance...Either lose money here or else where......is my luck right Now..
👍️0
Outcast27 Outcast27 3 년 전
Well the MMs are killing it.....Still holding ...Time will tell...The Virus keeps growing....Need Drugs...
👍️0
Outcast27 Outcast27 3 년 전
Thinking some News might be about to be released .....Hope So...
👍️0
Pedro2004 Pedro2004 3 년 전
Check-out the short-sale attack being done to ADGI.

👍️0
Pedro2004 Pedro2004 3 년 전
The problem with ADGI right now is the "Short Attack."

Ever since the GME short squeeze, and the amount of money the Shorts lost on GME -- I noticed the Shorts are ganging-up on companies. Combining their resources to make money on the drive down. And this always appears to happen when a company gets great news.

That's what happening to ADGI right now. The Shorts are attacking.
Eventually, it will go back up. But when, I don't know.

👍️0
Outcast27 Outcast27 3 년 전
Might Not be a Bad idea....Thinking same....I need to hold ADGI , Not going to take a 5k hit.....May Not Profit , but break even...is ok...
👍️0
Pedro2004 Pedro2004 3 년 전
I don't hold long-term right now. I have a bad feeling there's going to be another crash. Put 401K's into cash account.
👍️0
Man6677 Man6677 3 년 전
We will win , holding strong !

ADGI $$$
👍️0
Outcast27 Outcast27 3 년 전
This is pure BS. NO reason for this pull down , other than shake out shares...IMO
👍️0
Man6677 Man6677 3 년 전
Exactly Bud

ADGI $$$
👍️0
Outcast27 Outcast27 3 년 전
I think these MMs know they got a whale and going to pull every trick in the book.....Have already so why quit Now....$$$$$$$$ will go to the patience also....
👍️0
Man6677 Man6677 3 년 전
Good start today , with some good news it will pop

ADGI $$$
👍️0
Outcast27 Outcast27 3 년 전
Which one / ones do you hold long term ?
👍️0
Man6677 Man6677 3 년 전
I want to see GREEN here today

GLTA !
👍️0
Pedro2004 Pedro2004 3 년 전
I don't like to hold companies like this long-term. But I do have this on my radar.
👍️0
Pedro2004 Pedro2004 3 년 전
I'm never sure about anything.
👍️0
Jake L Jake L 3 년 전
ADGI - Friday Rundown, Monday Expectations

👍️0
Outcast27 Outcast27 3 년 전
Yep, Have a Great weekend...Stay Safe....It's spreading like wildfire...and ADGI has the answer......The Street will see the light...$ADGI
👍️0
Man6677 Man6677 3 년 전
The cards will be reshuffled next week

ADGI $$$
👍️0
Outcast27 Outcast27 3 년 전
These pricks did it last day dip....This tells me they really want in...Geess
👍️0
Man6677 Man6677 3 년 전
Exactly

ADGI $$$
👍️0

최근 히스토리

Delayed Upgrade Clock